ERBB2 and breast carcinoma: Of these, trastuzumab (HerceptinTM, Genentech/Roche, San Francisco, FL, USA) (Tmab) specifically binds to the extracellular domain IV of the aforementioned HER2 and has allowed the survival rate of patients who suffer from HER2-positive (HER2+) breast cancer to increase [6].